Navigation Links
Acella Pharmaceuticals, LLC, Files Abbreviated New Drug Application (ANDA) With the U.S. Food & Drug Administration
Date:2/21/2012

ATLANTA, Feb. 21, 2012 /PRNewswire/ -- Acella Pharmaceuticals, LLC, recently announced that it has filed an abbreviated new drug application (ANDA) for a product in the upper respiratory therapeutic area with the U.S. Food and Drug Administration (FDA). This filing represents the 5th ANDA Acella has waiting approval from the FDA, and the first filed under the leadership of Allen Fields, Acella's new VP, Head of Research and Development.  

"We are pleased with the FDA's acceptance of our filing," remarked Fields.  "I believe this latest filing speaks to the quality of work performed by our team, as well as to our continuous efforts to develop a strong pipeline of products for our internal and external customers."   

"This filing is another example of our investment in new products and expansion of our diversified product portfolio," added Acella CEO Mark Pugh.  "As always, Acella is committed to making quality healthcare more affordable for our customers."

About Acella Pharmaceuticals, LLC
Acella develops, markets, sells and distributes a broad portfolio of specialty pharmaceutical and other products in the areas of Dermatology, Women's Health, Pediatrics and other applications. Acella specializes in identifying and bringing to market quality, affordable products to customers and patients. For additional information please contact Acella at 678-325-5189.

 


'/>"/>
SOURCE Acella Pharmaceuticals, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Brookstone Pharmaceuticals, LLC becomes Acella Pharmaceuticals, LLC
2. Acella Pharmaceuticals, LLC Announces Its Acquisition of the PRENATE® Family of Trademarks and Associated Intellectual Property
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
6. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
7. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
8. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
11. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... Aug. 28, 2014  A candidate Ebola vaccine could be given ... and Mali as early as September, ... aimed at preventing the disease that has killed more than 1,400 ... . Human trials of this candidate vaccine, being co-developed ... to be accelerated with funding from an international consortium in response ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2Ebola vaccine trials fast-tracked by international consortium 2Ebola vaccine trials fast-tracked by international consortium 3Ebola vaccine trials fast-tracked by international consortium 4Ebola vaccine trials fast-tracked by international consortium 5Ebola vaccine trials fast-tracked by international consortium 6Ebola vaccine trials fast-tracked by international consortium 7
... of its commitment to supporting efforts to improve the ... has awarded $1,000 grants to ten health care organizations ... issues. (Logo: http://photos.prnewswire.com/prnh/20100412/DA84842LOGO ) ... the 2010 Beryl Institute Patient Experience grants are: ...
... PITTSBURGH, Oct. 19 Mylan Inc. (Nasdaq: MYL ... preferred stock issuance, the company has declared its quarterly dividend ... of 6.5% and a liquidation preference of $1,000.00 per share) ... of record as of Nov. 1, 2010.  Nov. 15, is ...
Cached Medicine Technology:Patient Experience Research Grants Awarded 2Patient Experience Research Grants Awarded 3
(Date:8/29/2014)... 2014 Most dentists work during normal business ... break in their day to be able to go see ... to find a few hours during their increasingly busy days. ... so important. It is now possible for people to get ... What is happening? , North York Dental has realized that ...
(Date:8/29/2014)... Washington MD (PRWEB) August 29, 2014 ... Expo at the Hyatt Regency Orlando last week August ... Greenstein returned as a presenter. , ... Reform in the 21st Century was a standing room ... Ah-hah Moments – Doctors of Chiropractic Leading the Way ...
(Date:8/29/2014)... 2014 Recent reports, backed by the ... today are working longer hours and taking fewer vacations ... Water believes that drinking lots of purified water can ... on their most popular and effective water purification systems ... until 9/2/2014, customers can save up to $125 off ...
(Date:8/29/2014)... 29, 2014 The Winscribe Board of ... Chief Executive Officer effective from 1st September 2014. Allen ... Winscribe. , “During this time of growth, there is ... said Matthew Weavers, Winscribe’s Founder and Chairman of the ... of commercial, IT and management experience gained in New ...
(Date:8/28/2014)... Fifty percent of adults who seek medical ... percent of Americans claim to have fatigue that is ... Fatigue is the most common yet overlooked cause of ... symptoms. Tasks that were once a breeze are now ... cause irritation, experiencing weight gain around the middle area ...
Breaking Medicine News(10 mins):Health News:North York Dental Provides Dental Services to Busy Professionals 2Health News:Sport and Spine Rehab’s CEO Presents at the Florida Chiropractic Association National Convention and Expo 2014 2Health News:Relax this Labor Day Weekend with Great Savings on Easy-Install, Do-It-Yourself Drinking and Whole House Water Filters 2Health News:Winscribe Names Greg Allen as CEO 2Health News:Peoria AlignLife Clinics Focus on Community Education 2
... E. Lachman has been awarded a $1.45 million five-year ... more about factors that can minimize memory declines in ... beliefs and behaviors that are tied to better memory ... and older adults believe that memory declines are inevitable ...
... Jobson Medical Information LLC,("JMI"), a leading ... it has acquired Gerber Communications ("Gerber") and,Practice ... leading,providers of custom publishing services and training ... acquisition expands JMI,s ability to,reach eye care ...
... Medical Center today,announced the use of an investigational, ... treatment of heart rhythm,disorders that can result in ... first performed in Texas as part of the ... taking place at up,to 25 hospitals throughout the ...
... other systemic uses of drugs to ... growth factor (VEGF), BOSTON, Feb. 13 New research ... the anti-cancer drug Avastin,which targets a growth factor responsible for ... certain patients.,Institute scientists mimicked the drug,s activity in mice and ...
... speech,pathologist and autism consultant Valerie Herskowitz will present ... the "Autism Through,the Lifespan" conference to be held ... now for an entire generation of children challenged ... and becoming young,adults with autism. Technology is the ...
... MALVERN, Pa., Feb. 13 A new study ... medical expenses reported,by auto injury claimants continue to ... economic losses (which include expenses for,medical care, lost ... claimants grew 9 percent annualized, from $5,520 in ...
Cached Medicine News:Health News:Brandeis researcher awarded grant to investigate memory and aging 2Health News:Jobson Medical Information LLC Acquires Gerber Communications and Practice Advancement Associates 2Health News:St. David's Medical Center First in Texas to Implement Visually Guided Catheter Ablation for Atrial Fibrillation 2Health News:VEGF Neutralization Can Damage Brain Vessels, Say Schepens Eye Research Institute Scientists 2Health News:A Sneak Peek Into the Special Needs Home of Tomorrow - Renowned Autism Consultant Valerie Herskowitz to Present Latest Findings at 'Autism Through the Lifespan' Conference February 14-17 in Orlando 2Health News:IRC Reports Claimed Medical Expenses for Auto Injury Claimants Far Outpace Inflation 2
15mm Open Blades, 28mm Maximum Spread; Available in small(S) and large (L), in stainless steel....
9mm Gently Curved Jaws, without lock; in Titanium....
8mm angled shaft with tip at 90 degree angle wtih rounded tear drop point; Tip available in left, right and center; (Right-SQT-225 and Left -SQT-227) In Titanium....
2.0mm Rounded Tip, 12mm From Tip to Bend Gently Curved, 15mm Shaft; In Titanium...
Medicine Products: